Cover Image: April 2005 Scientific American Magazine See Inside

Alzheimer's Vaccine?














Share on Tumblr



Image:

  • The Wisdom of Psychopaths

    In this engrossing journey into the lives of psychopaths and their infamously crafty behaviors, the renowned psychologist Kevin Dutton reveals that there is a...

    Read More »

Several years ago scientists at Elan, an Ireland-based drug company, and at U.S.-based Wyeth Pharmaceuticals developed a vaccine that showed promise in slowing the advance of Alzheimer's disease. The approach was to expose patients to a tiny amount of beta amyloid--the rogue protein thought to trigger the sticky plaques that accumulate in the brain. The exposure would prompt the body's immune system to raise its own disease-fighting antibodies to destroy the protein. But in January 2002, months into the clinical trials, it became apparent that serious brain swelling had developed in about 6 percent of patients. The trial was halted, hopes were dashed, and the researchers went back to square one.

Now investigators are recruiting people for a new trial. This time they will deliver the antibody itself to patients who have mild to moderate stages of the disease. Giving the antibody directly should not activate an immune response, says Dale Schenk, Elan's chief scientific officer. A faulty immune response is what causes dangerous swelling. And "it doesn't take much antibody" to see if the new approach is working, Schenk says.

Other scientists have confirmed that the antibodies protect against plaque buildup. Schenk says subjects in the earlier trial who showed an elevated antibody response performed significantly better on memory tests. Evidence from autopsied brains of some of those who died also indicated reduced plaque formation.

The new study will test different doses for safety. And scientists should be able to tell if the antibodies alleviate some of Alzheimer's devastating mind-robbing symptoms. Eli Lilly and others are also working on antibody treatments, but none have reached patients yet. Of the few medicines federally approved to treat Alzheimer's, most improve symptoms temporarily by boosting a brain chemical that is key to memory and learning.�


This article was originally published with the title Alzheimer's Vaccine?.



Buy This Issue
If your institution has site license access, enter here.

1 Comments

Add Comment
View
  1. 1. annejaa 02:41 AM 2/23/10

    Well Alzheimer's disease is a brain disorder which gradually destroys the ability to reason, remember, imagine, and learn. It's different from the mild forgetfulness normally observed in older people.In the early and middle stages of Alzheimer's disease, people with the illness may be painfully aware of their intellectual failings and what is yet to come. At this stage and throughout the course of the illness, it's vitally important to support their mental and emotional well-being with the help of their doctor, social worker, or psychological counsellor.Show them love, affection and warmth as they make their journey.I will keep visiting this site often.
    <a href="http://www.howtogetyourexbacknow.org/">you are the love of my life</a>

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

Follow Us:

See what we're tweeting about

Scientific American MIND

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Alzheimer's Vaccine?: Scientific American Mind

X
Scientific American Mind

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X